Browse articles from EyeWorld.org related to crosslinking. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA issues another response letter for dry eye NDA ➤ FDA denies approval for LHON NDA ➤ Commercial launch of epithelium-on crosslinking in the U.S. ➤ Company news ➤ ASCRS news and events
➤ FDA approves epithelium-on crosslinking treatment ➤ 12-month results from Phase 1/2 trial evaluating regenerative cell therapy for corneal endothelial disease ➤ Phase 3 data supports nonsteroidal treatment for uveitic macular edema ➤ FDA approves IDE for glaucoma device ➤ Company news ➤ ASCRS news and events
Two physicians discussed finding the right refraction in patients with keratoconus, what to take into account, and considerations if patients are seeking surgery.
➤ NDA submitted to the FDA for presbyopia drop ➤ FDA issues complete response letter to dry eye NDA ➤ FDA accepts BLA resubmission for bevacizumab to treat wet AMD ➤ One-month results in Phase 1/2 trial for treating Leber congenital amaurosis in a pediatric patient ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Transepithelial crosslinking NDA submission accepted ➤ Fast Track designation granted to drop being investigated for night driving impairment due to visual disturbances ➤ First-in-human interventional study for gene therapy treating Leber congenital amaurosis 4 ➤ Positive outcomes observed for geographic atrophy drug ➤ Regenerative Medicine Advanced Therapy designation granted to stem cell therapy for dry AMD ➤ ASCRS news and events
With new techniques in (or having recently completed) Phase 3 clinical trials to potentially move crosslinking to the next stage in the U.S., EyeWorld spoke with specialists to look back at where keratoconus monitoring and treatment was, where it is now, and what could be coming.
➤ Positive topline Phase 3 confirmatory trial results for transepithelial crosslinking ➤ 18-month data from first-in-human drug-eluting IOL ➤ New Phase 2 findings for investigational geographic atrophy treatment ➤ Study: long-term, low-dose antiviral treatment reduces risk for HZO patients ➤ Acquisition news ➤ ASCRS news and events
➤ Topline results for investigational first-in-class dry eye drop ➤ Dosing complete in second cohort of Stargardt disease gene therapy trial ➤ Enrollment complete for Phase 2 acute optic neuritis trial ➤ Enrollment complete for Phase 1/2a trial evaluating neovascular AMD therapy ➤ ASCRS news and events
➤ Enrollment complete in Phase 2 study for drug targeting endocannabinoid system for IOP lowering ➤ Dosing complete for Phase 1/2 trial evaluating a gene therapy for Stargardt disease ➤ Pre-Phase 3 Type B meeting held with FDA by company focused on retinitis pigmentosa ➤ Updates from several late-stage clinical trials ➤ New company launches to pioneer nonviral gene therapies ➤ ASCRS news and events
➤ Positive Phase 3 results in trial investigating topical diabetic macular edema treatment ➤ Positive topline results in Phase 3 trials for retinal vein occlusion treatment ➤ IND filed for drug to treat neuropathic corneal pain ➤ Trial for ‘first-in-class anti-VEGF-complement dual targeting drug’ begins dosing patients ➤ Complimentary access to video journal ➤ ASCRS news and events